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Abstract 
Background: A polyspecific, intrathecal humoral immune response against the neurotropic viruses, measles, rubella 
and varicella zoster virus, called “MRZ reaction” (MRZR), is present in the majority of patients with multiple sclerosis 
(MS). Neurosarcoidosis (NS) and acute disseminated encephalomyelitis (ADEM) are important clinical differential 
diagnoses of MS. Autoimmune encephalitis (AIE) represents a well characterized autoimmune CNS disorder with 
intrathecal antibody synthesis. The aim of this study was to investigate the specificity of MRZR for MS in patients with 
NS, ADEM and AIE for the first time, and to compare it with the diagnostic value of oligoclonal bands (OCB).
Patients and methods: Twenty-two patients with NS, 17 with AIE, 8 with ADEM and 33 with MS serving as controls 
were analyzed for OCB and MRZR by calculation of the antibody index (AI) for each virus. MRZR was considered as 
positive if at least two AIs were ≥1.5.
Results: A positive MRZR was statistically significantly less frequent in NS (9 %), AIE (11 %) and ADEM (0 %) compared 
to MS patients (70 %; p < 0.001 each). The specificity of MRZR for MS was 92 % in the study cohort. In comparison to 
MRZR, the OCB showed a higher sensitivity (100 %), but a lower specificity (69 %) for MS.
Conclusion: These results indicate that MRZR seems to be the most specific available CSF marker of MS.
Keywords: Multiple sclerosis, Intrathecal polyspecific antiviral immune response, MRZ reaction, Neurosarcoidosis, 
Acute disseminated encephalomyelitis, Autoimmune encephalitis
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Background
In 1992, Felgenhauer et  al. first described the polyspe-
cific, intrathecal humoral immune response against 
the most frequent three antigens, measles (M), rubella 
(R) and varicella zoster virus (Z), the ‘MRZ reaction’ 
(MRZR), as being highly specific for multiple sclerosis 
(MS) [1]. A positive MRZR is characterized by positive 
antibody indices (AI ≥ 1.5) for these three viruses, indi-
cating a polyspecific, intrathecal humoral immune 
response [1]. If, unlike in this study, MRZR is defined as 
at least one positive AI, more than 80 % of MS patients 
displayed a positive MRZR [1, 2]. The pathophysiological 
role of the MRZR in MS still remains elusive. Most likely 
it represents a polyspecific B cell activation (so-called 
‘bystander’ reaction) within the CNS, because simulta-
neous infection with several neurotropic viruses is very 
unlikely, and polymerase chain reaction (PCR) tests failed 
to demonstrate viral DNA in CSF from MRZR-positive 
MS patients [3]. Oligoclonal bands (OCB) represent 
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a sensitive CSF marker of MS, occurring in 90–98  % of 
patients throughout the course of the disease [4]. How-
ever, OCB are also positive in infectious CNS disorders, 
such as neuroborreliosis (OCB in 70 % [5]), and in auto-
immune CNS disorders such as neuromyelitis optica 
(NMO; OCB in >30 % [6]), and thus are much less spe-
cific than MRZR.
Apart from MS, prevalence of MRZR has been stud-
ied in two other autoimmune CNS diseases: paraneo-
plastic neurological disorders (PND) [7] and NMO [8]. 
Additionally, there is only one case series reporting posi-
tive MRZR in a very few patients with systemic autoim-
mune disorders with CNS involvement including one 
patient with neurosarcoidosis (NS), three patients with 
systemic lupus erythematosus and one patient each with 
Wegener`s granulomatosis and Sjögren syndrome [9].
Occasionally, especially using the revised McDonald 
criteria [10], the correct diagnosis of MS at initial clini-
cal presentation can be difficult, particularly if there are 
hints towards differential diagnoses such as NS or acute 
disseminated encephalomyelitis (ADEM). In such clini-
cal situations, it would be helpful to know how well the 
MRZR distinguishes between MS and these differen-
tial diagnoses. From a more pathophysiological point 
of view, Jarius et  al. questioned in 2009 if the MRZR is 
specific to MS at all or should rather be considered as a 
general marker for CNS autoimmune diseases [11]. In 
this regard, autoimmune encephalitis (AIE) is a well char-
acterized example of CNS autoimmunity suitable for fur-
ther investigation of the specificity of MRZR. The present 
study is believed to be the first to systematically address 
the frequency of a positive MRZR in NS, ADEM and AIE.
Methods
Patients
For the purpose of this retrospective study, NS, AIE 
and ADEM patients treated either at the Department of 
Neurology or at the Department of Neuropediatrics and 
Muscle Disorders, University Medical Center Freiburg 
in Germany, from 2005–2014, were identified through 
a systematic search of clinic databases. An MS control 
group was derived from the control group (18 OCB posi-
tive MS patients) from a previous study [11], augmented 
to sufficient size (n =  33) by random selection from all 
MS patients treated at the same clinic over the same 
period. Patients were only enrolled if CSF/serum sam-
ples were still available after completion of all clinically 
necessary tests. Diagnoses of MS, NS and ADEM were 
established according to internationally accepted consen-
sus criteria (MS [10]; NS [12]; and ADEM [13]) and after 
careful exclusion of relevant differential diagnoses. AIE 
was diagnosed in the presence of subacute clinical fea-
tures typical for limbic encephalitis (seizures, affective or 
memory disorders) and detection of a well characterized 
IgG antibody against neuronal surface proteins (such as 
voltage-gated potassium channel (VGKC), N-methyl-
d-aspartate receptor (NMDAR), gamma-aminobutyric 
acid B receptor (GABAB-R) or glutamic acid decarboxy-
lase (GAD)) and after careful exclusion of relevant differ-
ential diagnoses. Lumbar puncture (LP) was performed 
with the written consent of all patients. As LP was per-
formed for the purpose of initial diagnosis, almost all 
patients were untreated at the time of LP. CSF and serum 
samples were taken on the same day and stored according 
to consensus protocol for the standardization of cerebro-
spinal fluid collection and biobanking [14]. Haemolytic 
CSF specimens were excluded. Data concerning patients’ 
immunization status were not available. All NS, AIE and 
ADEM patients were included who matched these cri-
teria. The ethics committee of the University Medical 
Center Freiburg approved the study.
Determination of MRZR and OCB
IgG concentrations in the serum and CSF were deter-
mined nephelometrically (ProSpect System, Siemens, 
Germany) and Measles-, Rubella- and Varicella-IgG 
levels in the CSF and serum were measured by enzyme-
linked immunosorbent assay (Serion classic ELISA, Ger-
many), both according to the manufacturer’s instructions. 
Assessment of the MRZR was performed with analysis of 
virus-specific AIs against M, R, and Z in the Department 
of Virology, University of Freiburg, Germany according 
to Reiber’s formula [15]. An AI is a mathematical param-
eter to assess whether antibodies detected in CSF are 
derived from blood and have diffused through the blood-
CSF barrier (low AI; e.g. <1.5) or have been intrathecally 
produced. In this study, a virus-specific AI ≥1.5 was con-
sidered as indicative of intrathecal antibody production 
against the respective virus, M, R, or Z. The MRZR was 
assessed as positive if at least two AIs indicated intrathe-
cal virus-specific antibody production, a definition which 
has been used by a number of researchers [8, 9, 16, 17]. If 
an AI could not be calculated due to non-detectable anti-
bodies in the CSF, AI was graded as one.
Detection of OCB was performed in a specialized rou-
tine laboratory (Department of Neurology, Freiburg), 
using a high-sensitive isoelectric focusing technique on 
agarose gel followed by immunofixation (Hydragel Isofo-
cusing, Sebia, France) as described earlier [11]. Absence of 
OCB was assumed if there was ≤1 OCB exclusive in CSF.
Statistical comparisons of MRZR results between 
groups were performed using Fisher’s exact test (two-
tailed). Mean AIs of M, R and Z were compared between 
study groups using the Kruskal–Wallis test with Dunn’s 
test. A p value  <0.05 was regarded as statistically 
significant.
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Results
Of the total population in the database of first-diagnosis 
NS (n = 201), AIE (n = 25) and ADEM (n = 41), many 
patients were excluded due to unsure diagnosis or where 
the diagnosis was later corrected (NS: n  =  169, AIE: 
n =  0 and ADEM: n =  28). Of the remaining patients, 
there was not enough CSF/serum available for deter-
mination of MRZR in a few patients (NS: n =  10, AIE: 
n =  6 and ADEM: n =  5). Finally, 22 patients with NS, 
19 with AIE and 8 with ADEM were analyzed for MRZR. 
Thirty-three patients with MS served as a control group. 
Demographic and clinical data of all study patients are 
presented in Table 1.
There were some demographic differences between the 
four groups, e.g., more women within the MS group and 
younger ADEM patients. Due to non-detectable antibod-
ies in the CSF, some AIs were graded as one (applicable 
to 9/99 AIs of MS patients, 5/66 AIs of NS patients, 11/57 
AIs of AIE patients and 8/24 AIs of ADEM patients).
The majority of MS patients (70 %) showed a positive 
MRZR (16/33 had two positive AIs and 7/33 all three). 
In contrast, a positive MRZR was much less frequent in 
patients with NS (9  %; p =  0.0001; 1/22 with two posi-
tive AIs and 1/22 all three), AIE (11 %; p = 0.0001; 2/19 
with two positive AIs) and ADEM (0  %; p =  0.0005) as 
presented in Fig. 1. Accordingly, specificity of MRZR for 
MS was 91.5 % and likelihood ratios were 8.2 (LR+) and 
0.3 (LR−). Mean AI values for M, R and Z in NS, AIE 
and ADEM were all less than 1.5 (range 0.4–8.4, SD 0.8) 
whereas the MS group revealed mean AI values greater 
than 3.0 for all three viruses (range 0.5–40.0, SD 5.6) as 
shown in Fig. 2. Among the 49 non-MS patients, only 3 
AIs (representing 2  % of the entire 147 non-MS MRZ-
AIs) exceeded 3, and 13 AIs (9 %) lay between 1.5 and 3.0. 
AIs for R of NS/AIE/ADEM patients, AIs for M of AIE/
ADEM patients and AIs for Z of NS patients were statis-
tically significantly lower compared to MS patients. No 
other statistically significant differences between AIs of 
MS patients and non-MS patients were found.
All MS patients and 31 % of non-MS patients showed 
OCB in CSF (OCB prevalence in NS 41 %, AIE 32 % and 
ADEM 0 %), which corresponds to a specificity of OCB 
for MS of 69 % in this study cohort.
Discussion
To our knowledge, this is the first systematic study 
describing a high MRZR specificity for MS (92  %) in 
patients with NS, ADEM and AIE. The MRZR sensitiv-
ity found here, 70 %, is in line with the two largest previ-
ous studies (72 % according to Felgenhauer [1] and 67 % 
according to Reiber [2]) if the same MRZR definition 
(at least two positive AIs) is applied to their data. In this 
study, AIs for MRZ in NS, AIE and ADEM were con-
sistently lower than the values of MS patients, although 
in the small sample not all differences reached statisti-
cal significance. Should a single MRZ-AI be considered, 
according to our results, an AI value between 1.5 and 3 is 
not highly specific for MS; whereas an AI >3.0 would reli-
ably support the diagnosis of MS in this clinical context 
(CNS infection with the respective virus is very unlikely 
or excluded). Apart from that, MS patients usually show 
more than one positive MRZ-AI.
As expected, OCB were more frequent in MS patients, 
but less specific compared to MRZR. Considering the 
very low rate of a positive MRZR in infectious CNS dis-
eases, such as neuroborreliosis [18] or viral myelitis [19], 
and other autoimmune CNS disorders, such as NMO [9] 
or PND [8], these results provide evidence of particularly 
high specificity of MRZR compared to other diagnostic 
tools. Reasons for the high MS specificity of MRZR are 
Table 1 Demographic and clinical data of enrolled patients
n number of patients, SD standard deviation, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive 
multiple sclerosis, VGKC voltage-gated potassium channel, NMDAR N-methyl-d-aspartate receptor, GAD glutamic acid decarboxylase GABAB-R γ-aminobutyric acid B 
receptor
Diagnosis Multiple sclerosis Neurosarcoidosis Autoimmune encephalitis Acute disseminated encepha-
lomyelitis
n 33 22 19 8
Mean age in years (range; SD) 47.8 (23–73; 11.8) 54.7 (31–83; 15.0) 56.2 (31–84; 16.7) 30.6 (4–63; 17.8)
Gender, females in % 69.7 40.9 36.8 50.0
Additional clinical details MS types:
 RRMS: n = 14
 SPMS: n = 5
 PPMS: n = 14
Most frequent neurologic/
radiologic syndromes:
 myelitis: n = 6
 subcortical cerebral lesions: 
n = 6
 hydrocephalus: n = 3
 brainstem nerve palsy: n = 3
 meningitis: n = 2
Detected antibodies against:
 VGKC: n = 12
 NMDAR: n = 5
 GAD: n = 2
 GABAB-R :n = 1 (1 patient 
had VGKC- and NMDAR-
antibodies)
Neurologic syndromes in addi-
tion to encephalopathy:
 brainstem syndrome: n = 3
 hemisyndrome due to cerebral 
lesions: n = 3
 cerebellar syndrome: n = 1
 myelitis: n = 1
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enigmatic and remain to be addressed in pathophysiolog-
ical studies.
MRZR is not yet required in the standard diagnos-
tic procedure for patients suspected of MS. This is most 
likely due to costs and reduced significance of CSF analy-
sis in the 2010 revised McDonald criteria, which has been 
critically discussed by a group of European authors [20]. 
The findings of the present and earlier studies lend weight 
to the proposal that MRZR become part of the recom-
mended diagnostic procedure in cases of suspected MS. 
Difficulties in ruling out MS mimics (e.g., ADEM, NS and 
NMO) are not uncommon, as these disorders can reveal 
similar MRI and routine CSF findings (including OCB). 
Because these MS mimics require substantially differ-
ent treatment and have different prognoses, it is cru-
cial not to misdiagnose them as MS [21–23]. Although 
ADEM often is considered in pediatric patients, MRZR 
can be used for distinction from MS since it was found 
to be already positive in the majority of prepubertal MS 
patients [24]. Determination of MRZR might be helpful 
in this context due to its high specificity as shown in this 
and previous studies [7, 8].
The clinic database includes neurosarcoidosis in the 
more general diagnostic category “sarcoidosis affect-
ing other localizations than lungs, lymph nodes or 
skin”. Therefore, many patients in this category had to 
be excluded who showed no involvement of the nerv-
ous system. None of the AIE patients had to be excluded 
due to incorrect diagnosis, most likely as a consequence 
of searching only for patients with a proven well defined 
antibody, which obviously enables very high diagnostic 
certainty.
There are some limitations of this study. First, age and 
gender of the four groups (MS, NS, AIE and ADEM) were 
not well balanced due to enrolling unmatched patients 
because of the rarity of the last three disorders. Second, a 
selection bias in the monocentric tertiary hospital cohort 
is conceivable. Third, in view of the small sample size, the 
retrospective design and the lack of immunization status 
information, the results should be tested further. A larger 
cohort of ADEM patients would be advantageous, as 
would tests in other areas of the world. Extending stud-
ies geographically is important because the prevalence 
of positive AIs differs with immunization status, as evi-
denced by the lower frequency of intrathecal rubella anti-
body synthesis in Cuban MS patients [25].
Conclusions
This study found MRZR to have a specificity of more than 
90 % for MS, underlining its high potential as a relevant 
diagnostic marker in clinical practice. Future systematic 
investigations of MRZR in patients with other challeng-
ing differential diagnoses of MS, such as CNS vasculitis 
or CNS lymphoma, might be helpful, although for these 
rare diseases biopsy will remain the diagnostic reference 
standard.
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